Premium
Clinical care and other categories posters: structure‐systems of care and healthcare delivery
Author(s) -
A Ramaesh,
Sarah H. Wild,
Timothy Robbins,
Syed Wasif Gillani,
BM Singh,
Kate Fayers,
Kareen J. I. Thorne,
M Mcdonald,
Charlotte Atkinson,
Sophia Woodman,
Hermione Price,
S Mennear,
Jane Beith,
AP Jones,
Brenda Lomax,
Karunakaran Vithian,
Charles Bodmer,
Sonu Goel,
Sinéad Smyth,
Jessica Streeting,
Zayd Tippu,
Harshana Liyanage,
Ana Correa,
David Burleigh,
AP McGovern,
Simon Jones,
Simon de Lusignan,
Alex Harrington,
Joanna Bridger,
Jyothish Govindan,
R Estelrich,
Prashant Patel,
Ros Levenson,
David A. Thomas,
Punith Kempegowda,
Bryony Coombs,
Vraj Shah,
Amy Phillips,
Lisa Peters,
Rebecca Skelding,
Umesh Salanke,
P Reddy-Kolanu,
Sandip Ghosh,
Parth Narendran
Publication year - 2016
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.51_13048
Subject(s) - medicine , citation , health care , healthcare delivery , exhibition , library science , family medicine , nursing , art history , computer science , law , art , political science
Aims: Dipeptidyl peptidase-4 (DPP-4) inhibitors are recommended second or third line therapy in type 2 diabetes and have become widely prescribed in primary care. We present a description of their current use and prescribing trends in UK primary care. Methods: A cohort of people with type 2 diabetes (N=34,278) was identified from the University of Surrey-Lilly Real World Evidence (RWE) centre database, using routinely collected primary care data. Monthly prescription data was extracted from primary care records on the use of DPP-4 inhibitors in this group. We report prescription numbers over time and the demographics of people prescribed these medications. Results: We found DPP-4 inhibitors were commonly prescribed with 6,306 (18.4%) people with type 2 diabetes initiated on them since January 2008. Prescription rates are continuing to climb with a maximum rate at the end of our study period (March 2015) of 1108 prescriptions per 10,000 people with type 2 diabetes per month. The mean age of those prescribed DPP-4 inhibitors was 63.5 (SD 12.3) years with a mean body mass index (BMI) of 32.1 (SD 6.2) kg/m2. People living in areas of highest deprivation were less likely to be prescribed DDP-4 inhibitors (most deprived two quintiles 17.1% of people prescribed a DPP-4; 95% CI 16.7-17.5%, least deprived three quintiles 20.3%; 95% CI 19.8-20.9%). Conclusions: DPP-4 use is now common and continues to increase. Use of these medications is lowest in the most deprived areas where diabetes control is often worst